# EDGAR Filing Document

**Accession Number:** 0001889109
**File Stem:** 0001104659-26-037376
**Filing Date:** 2026-3
**Character Count:** 4598
**Document Hash:** 13a43a7d4dbcab2f2eb7138602556f8b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-037376.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001104659-26-037376

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BELITE BIO, INC
- **CENTRAL INDEX KEY:** 0001889109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41359
- **FILM NUMBER:** 26817115

**BUSINESS ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 858-246-6240

**MAIL ADDRESS:**
- **STREET 1:** 12750 HIGH BLUFF DRIVE SUITE 475
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15b-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

Commission File Number: 001-41359

**Belite Bio, Inc**

(Exact name of registrant as specified in its charter)

**Not Applicable**

(Translation of Registrant´s name into English)

**12750 High Bluff Drive Suite 475, San Diego, CA 92130**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

On March 31, 2026, Belite Bio, Inc issued a press release entitled "Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website". A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**EXHIBIT INDEX**

[Exhibit 99.1 — Press Release](tm261133d2_ex99-1.htm)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Belite Bio, Inc** | **Belite Bio, Inc** |
| By: | /s/ Yu-Hsin Lin |
| Name: | Yu-Hsin Lin |
| Title: | Chief Executive Officer and Chairman |

---

Date: March 31, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](tm261133d2_ex99-1img001.jpg)

**Belite Bio Announces Availability of Annual Report on Form 20-F**

**Through Company Website**

SAN DIEGO, March 31, 2026 - Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https://<u>www.belitebio.com</u>). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

**About Belite Bio**

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on <u>X</u>, <u>Instagram</u>, <u>LinkedIn</u>, and <u>Facebook</u>, or visit us at <u>www.belitebio.com.</u>

**Media and Investor Relations Contact:**

Jennifer Wu

<u>ir@belitebio.com</u>

Julie Fallon

<u>belite@argotpartners.com</u>